UPC Analytics
DEEN
Übersicht · Eingereicht: 13. Nov. 2025

UPC_CoA_906/2025

Methods of Using Sustained Release Aminopyridine Compositions

BerufungenHauptberufungCourt of AppealAppealCase Closed
ÜbersichtEntscheidungenZitateDokumenteZeitverlauf
Parteien

Kläger

  • Merz Pharmaceuticals LLC
  • Merz Therapeutics GmbH
  • Merz Pharma France
Vertreter: Laëtitia Bénard (Allen & Overy Shearman Sterling LLP); (Carpmaels & Ransford LLP)

Beklagte

  • Viatris Santé
Vertreter: Marc Lauzeral (Schertenleib)
Richter
  • Rian Kalden
  • Patricia Rombach
  • Ingeborg Simonsson
Patente
  • EP2377536
CPC-Codes: A61P43/00, A61P19/08, A61K31/435, A61P25/28, A61K9/20, A61K31/44, A61P21/00, A61P17/02, A61K31/4409, A61P25/00

Sektor: Pharmaceutical & Medical

Ausgang
Abgewiesen
Eingereicht: 13. Nov. 2025
Erste Entscheidung: 19. Dez. 2025
Sprache: English

The Court of Appeal disposed of Viatris's procedural appeal (UPC_CoA_906/2025) under R.220.2 RoP as devoid of purpose under R.360 RoP. The procedural appeal concerned the Paris Local Division's panel review order confirming disregard of certain Viatris exhibits as late-filed. The Court found the appeal had no purpose because, after Viatris had filed this procedural appeal, the Paris Local Division issued its final order of 21 November 2025 rejecting Merz's application for provisional measures in Viatris's favour. Viatris could instead raise the issue of the excluded exhibits in the separate merits appeal (UPC_CoA_917/2025) brought by Merz against that final order.

Im UPC-Register öffnen